Education
About Us
Working with TipRanks
Follow Us
Genelux Corp. (GNLX)
NASDAQ:GNLX
GNLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.95 - $5.89
Previous CloseN/A
Volume23.79K
Average Volume (3M)135.67K
Market Cap
$155.25M
Enterprise Value$82.64M
Total Cash (Recent Filing)$27.97M
Total Debt (Recent Filing)$1.71M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Nov 12, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding37,773,440
10 Day Avg. Volume188,807
30 Day Avg. Volume135,668
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue92.23
Enterprise Value/Gross Profit-139.12
Enterprise Value/Ebitda-2.71
Forecast
1Y Price Target
$18.50Price Target Upside350.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical Trials SuccessGenelux announced positive initial data from its investigator-sponsored ongoing P1b/2 study evaluating systemically administered Olvi-Vec + platinum chemotherapy in patients with platinum-relapsed or platinum-refractory small cell lung cancer.
Financial StabilityThe company announced an equity financing for $10.5M in gross proceeds, which combined with its cash, should provide runway into 2026, through the P2 interim in NSCLC and potentially the top-line P3 readout.
Regulatory SupportThe FDA recommended adding an interim overall survival analysis to the progression-free survival primary endpoint in the P3 ovarian cancer trial, which could support full approval without needing a confirmatory trial.
Bears Say
Financial ChallengesGenelux reported a net loss, which may indicate financial challenges despite having a cash runway expected to last into the second half of 2026.
Treatment Efficacy ConcernsResponse rates for treatment of second-line non-small cell lung cancer with CPIs are slightly higher than second-line chemotherapy, but patients receiving Olvi-Vec for recurrent NSCLC would have already progressed on CPIs, meaning the expected efficacy for these patients would be even lower.
Genelux Corp. News
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $1.95 and its highest was $5.88 in the past 12 months.
What is Genelux Corp.’s market cap?
Genelux Corp.’s market cap is $155.25M.
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is Nov 12, 2025 which is in 48 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on Aug 07, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.216 by $0.016.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -0.22.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 37,773,440 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.216. Following the earnings report the stock price went down -5.689%.
Which hedge fund is a major shareholder of Genelux Corp.?
Among the largest hedge funds holding Genelux Corp.’s share is Highbridge Capital Management LLC. It holds Genelux Corp.’s shares valued at 0.
Genelux Corp. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.50 (350.12% Upside)
$18.50 (350.12% Upside)
Hedge Fund Trend
Decreased
By 631.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.13%
12-Months-Change
Fundamentals
Return on Equity
-98.72%
Trailing 12-Months
Asset Growth
-28.62%
Trailing 12-Months
Company Description
Genelux Corp.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
GNLX Stock 12 Month Forecast
Average Price Target
$18.50
▲(350.12% Upside)
Technical Analysis
Ownership Overview
14.62% Insiders
4.73% Mutual Funds
9.23% Other Institutional Investors
67.93% Public Companies and
Individual Investors